Search Results for: 19

— Study to Evaluate Effect of SYN-010 in Reducing Methane Production in the Gut — — Methane Production is Perceived as the Underlying Cause of Pain, Bloating and Constipation Associated with IBS-C — ROCKVILLE, Md., June 29, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the […]

— Study to Evaluate SYN-004’s Antibiotic-Degrading Effect in the Gut in the Presence of Esomeprazole — ROCKVILLE, Md., June 12, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, dosed the first participant in a second Phase 2a clinical trial of

— Successful Clinical Development Would Enable Company’s Microbiome-Protecting Therapeutics to Cover all Three Beta-Lactam Antibiotic Classes — — Webcast Details Below for Microbiome Analyst & Investor Meeting Live Today at 9:00 a.m. EDT — ROCKVILLE, Md., June 3, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), this week presented initial data that support the

— GI Clinician and Scientist Most Recently Served in Leadership Positions at Quintiles and the U.S. Food & Drug Administration (FDA) — ROCKVILLE, Md., June 2, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced Klaus Gottlieb, MD, FACG, has

— Leading Clinicians to Discuss Novel Approaches to Treating IBS-C and Preventing C. difficile — — Webcast Scheduled at 9:00 a.m. EDT on Wednesday, June 3, 2015 — ROCKVILLE, Md., June 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific

— Company’s Program for Prevention of C. difficile Infection in Phase 2a Clinical Trial and on Target for Phase 2b Clinical Trial Initiation in 2H 2015 — ROCKVILLE, Md., May 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases,

— Company’s Irritable Bowel Syndrome with Constipation (IBS-C) Program to Reduce the Impact of Methane Gas in the Gut on Target to Initiate Phase 2 Clinical Trial in 2Q 2015 — ROCKVILLE, Md., May 18, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome

— Initiated Phase 2 for Prevention of C. difficile, Expected to Initiate Phase 2 for IBS-C by end of June 2015, and Expanded Leadership Team as Company Moves into Next Development Stage — — Conference Call Today, May 11, 2015, at 4:30 p.m. EDT — ROCKVILLE, Md., May 11, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE

— Appointment Reflects Company’s Expanded Clinical and Market Driven Focus — ROCKVILLE, Md., May 7, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced Maureen Early joined the team in the newly created position of Vice President, Commercial. In her

— Executive Brings Significant Biotech Industry Leadership Experience to Team as Company Enters Next Phase of Development — ROCKVILLE, Md., May 4, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapeutics focused on protecting the microbiome, as well as treating other diseases, announced Steven A. Shallcross has been appointed Chief Financial